drugset / Trial / NCT06988124

Dexamethasone Palmitate for PONV After Craniotomy

NCT06988124

Recruiting 500 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.

Timeline

Start
2025-06-25
Primary completion
2027-05-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 5 mg Intravenous
Subject Dexamethasone Palmitate Other / unclassified 8 mg Intravenous

Indications

No indication recorded.